Skip to content
Biotechnology, Business Company News

ReNerve Limited Expands into Mexico – Exclusive NervAlign® Nerve Cuff Distribution Partnership with Imbiomex

Jane Morgan Management 2 mins read

ReNerve Limited (ASX:RNV) (“ReNerve” or “the Company”) is pleased to announce it has signed an exclusive distribution partnership agreement with Imbiomex, a leading Mexican medical device distribution company, in order to progress the NervAlign® Nerve Cuff through regulatory approval and commercial distribution in Mexico.

Highlights

  • ReNerve partners with Imbiomex to secure regulatory approval and launch the NervAlign® Nerve Cuff in Mexico.

  • The Mexican nerve repair biomaterials market is valued at USD$74M annually, with a projected 17% growth rate.

  • This agreement strengthens ReNerve’s presence outside the US, as part of its ongoing global expansion strategy, unlocking new opportunities in Latin America.

Commenting on the new partnership, ReNerve CEO, Dr Julian chick, stated: “We are delighted to be partnering with the Imbiomex team to establish a market presence in Mexico, as part of our broader global expansion strategy. We are especially excited to work with Imbiomex for the Mexican market, given their strong local positioning, as well as their in-depth understanding of the biomaterials and surgical markets, including the peripheral nerve repair market.”

About the NervAlign® Nerve Cuff

The NervAlign® Nerve Cuff is an advanced bioabsorbable technology designed to protect and support nerve repair during the healing process, typically after peripheral nerve injury surgeries. It is uniquely designed to: 

  • Safeguard repaired nerves while promoting natural regeneration. 

  • Naturally absorbs within six months, leaving only regenerated tissue. 

Market Potential in Mexico 

Mexico represents a growth opportunity for nerve repair biomaterials. Imbiomex, with over a decade of experience in the biomaterials sector, will import, market, and distribute the NervAlign® Nerve Cuff, ensuring effective market penetration. 

Next Steps

  • Regulatory submission process underway to secure Mexican market approval.

  • Imbiomex to lead commercialisation efforts upon approval.

  • Further expansion planned across Latin America as part of ReNerve’s growth strategy.


About us:

About ReNerve Limited

ReNerve Limited (ASX:RNV) is a medical device company specialising in advanced nerve repair and regeneration solutions. The Company is focused on commercialising innovative medical devices and tissue-engineering products to address unmet needs in peripheral nerve repair. ReNerve acknowledges AusIndustry’s Accelerating Commercialisation program for its support in commercialising the NervAlign® Nerve Cuff.

For more information, visit www.renerve.com.au


Contact details:

Jane Morgan
Jane Morgan Management
Investor & Media Relations
[email protected]

Media

More from this category

  • Business Company News, Community
  • 14/01/2026
  • 09:50
Victorian Chamber of Commerce and Industry

Victorian Chamber launches free helpline and support hub for bushfire-impacted businesses

The Victorian Chamber of Commerce and Industry is urging businesses across Victoria’s fire-affected regions to reach out for support, launching a dedicated 2026 Bushfire HR Support Helpline and a regularly updated online resource hub to help operators navigate recovery. With many regional employers facing damage, disruption, workforce issues and uncertainty, the Victorian Chamber is providing free, practical guidance to businesses located in declared State of Disaster areas impacted by the January 2026 bushfires. The Victorian Chamber’s workplace relations advisers can assist with urgent HR and employment questions, including: • Pay and leave options if staff are stood down • Employee…

  • Contains:
  • Biotechnology, Science
  • 14/01/2026
  • 09:30
OmnigeniQ

Australian start-up unveils world-first physics model to visualise human proteins

Australian companyOmnigeniQ has revealed the first computer model of a human protein as it exists in the body, confirming that native protein topology can be calculated directly from physics. The breakthrough was achieved using the company’s physics-based Deterministic Intelligence model that shows proteins in their native, hydrated, dynamic form – something existing tools cannot do. This milestone supports OmnigeniQ’s mission to build the world’s first holographic twin of the human body, enabling more preventative, predictive and precise medicine. OmnigeniQ has unveiled a world-first scientific milestone at Biotech Showcase in San Francisco, demonstrating the first deterministic computation of Cyclin-dependent kinase 5…

  • Business Company News, Manufacturing
  • 13/01/2026
  • 22:35
Digital Science

U.S. Patent Applications Decrease Dramatically One Year After Reaching Record High, Falling 9%

NEW HAVEN, CT, UNITED STATES, January 13, 2026 / 2025 Rankings Highlight Strong Focus on Sustainability in R&D: Half of the Patent Areas on the Top 10 Fastest Growing Technologies Relate to Batteries. Recovering Usable Material From Waste Also Figures Prominently, According to Annual Patent Study by IFI CLAIMSAfter seven years of growth, U.S. patent applications headed sharply downward, dropping 9% from 2024, the lowest level since 2019. Other 2025 results show a slight decline in the number of U.S. patents granted, down less than 1% from 324,064 in 2024 to 323,272 in 2025. Samsung retained the top spot for…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.